YRK York Pharma

    Sinclair Pharma announces sales collaboration with York Pharma         

22nd December 2008, Godalming, UK: Sinclair Pharma plc ("Sinclair": SPH:L), the
international specialty pharmaceutical company, announces today that it has
entered into a commercial collaboration with York Pharma in the UK. Under the
terms of the agreement each company will co-promote selected products to
dermatologists and selected GP's.

Sinclair Pharma's sales force will co-promote certain York Pharma products
including the anti-acne product Zindaclin and the emollient QV. York Pharma's
sales force will co-market Sinclair's Atopiclair product for atopic dermatitis.
The agreement comes into force in January 2009 and relates specifically to the
UK market.

Dr Michael Flynn, CEO of Sinclair Pharma said:

"This agreement effectively doubles the number of specialist salespersons
promoting the two companies' dermatology product in the UK. For Sinclair this
is particularly important for the promotion of our reimbursed product
Atopiclair for the treatment of atopic dermatitis. We are exploring similar
synergies with York in other European countries"

Terry Sadler, Chief Executive of York Pharma, added:

"We're delighted to be working with Sinclair Pharma, initially in the UK
market, where York has a number of approved products which can be promoted to
both GP's and Dermatologists. We believe this collaboration will help optimise
the value of York Pharma's portfolio and accelerate our sales growth ahead of
the anticipated commercialisation of Abasol in the UK in 2009."

In addition to the agreement announced today, discussions between the two
companies are ongoing to evaluate the expansion of the co-marketing
relationship into other key European territories.

                                    -ends -                                    

For further information please contact:

Sinclair Pharma plc Tel: +44 (0) 1483 410 600

Dr Michael Flynn, CEO

Jerry Randall, CFO

Mariyam Rawat, Communications & Investor relations MRawat@sinclairpharma.com

Capital MS&L

Mary Clark, Anna Mitchell Tel +44 (0)20 7307 5340

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company.  It
has a growing sales and marketing operation that is already present in France,
Italy, UK, Spain and Portugal, and a complementary marketing partner network
that spans more than 80 countries.

Sinclair has proven expertise in acquiring or developing commercially
attractive and undervalued products, registering these products and bringing
them to market within a short timeframe.  Sinclair focuses on niche therapeutic
areas and its current portfolio includes products for dermatological conditions
and oral health.

About York Pharma PLC www.yorkpharma.com

YORK PHARMA PLC is a pharmaceutical Group, established in 2003, which develops,
markets and supplies branded dermatological products to pharmaceutical
wholesalers, hospitals and general practitioners within the field of
dermatology.

The Group currently has at its disposal more than 20 patent families (with over
100 individual patents/patent applications) and intellectual property in
relation to its portfolio of novel dermatology products and technology
platforms in the key therapeutic areas of fungal infection, eczema, psoriasis,
vitiligo and acne that make up more than 87% of the global $10bn dermatology
market.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act
of 1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995. Actual results of events could differ materially from those described in
the forward-looking statements due to a variety of factors.

                                                                               


END

York Pharma (LSE:YRK)
Historical Stock Chart
From May 2024 to Jun 2024

York Pharma (LSE:YRK)
Historical Stock Chart
From Jun 2023 to Jun 2024